Novo Nordisk’s $1.2 Billion Investment in Denmark Explained
🔹Novo Nordisk has announced a major investment of DKr8.5bn ($1.2bn) to establish a new production facility in Odense,…
Global Pharma News
USFDA Approves Granules Pharmaceuticals’ Generic Vyvanse Chewables
Granules Pharmaceuticals, Inc. has successfully received USFDA approval for its bioequivalent generic version of Lisdexamfetamine Dimesylate Chewable Tablets…
How Science Revolutionized Medicine💊 and Healthcare🏥
The essay captures the transformative impact of science on various aspects of human life, emphasizing its pivotal role…
MHRA Extends Licence for Blincyto: What It Means for ALL Patients🪪
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for Amgen’s Blincyto (blinatumomab), expanding…
Cipla has launched India’s first inhalable insulin
🔷Cipla has launched India’s first inhalable insulin, Afrezza, after receiving approval from the Central Drugs Standard Control Organisation…
The Role of the Tumor Microenvironment in Immune Checkpoint Pathways
The tumor microenvironment (TME) is indeed a critical determinant of cancer progression and immune evasion. Its dynamic and…
Inhibition of Cell Apoptosis Signals and Immune Evasion
♦️Cancer cells use complex mechanisms to evade immune surveillance, with inhibition of apoptotic signaling being a key strategy.…
Innovations in Media Fill Testing: What the Pharmaceutical Industry Needs to Know
The advancements in pharmaceutical manufacturing technologies, particularly in media fill testing, represent a significant leap forward in ensuring…
Global Orally Disintegrating Tablet (ODT) Market is expected to exceed more than US$ 26.50 Bn by 2025 at a CAGR of 11.5% in the given forecast period
Global Orally Disintegrating Tablet Market Overview: An Orally Disintegrating Tablet is a drug dosage form available for a…
INNOVATION VERTE : INSIDE LOOK AT PUNE’S LUPIN RESEARCH PARK R&D FACILITIES
Lupin Limited, a prominent global pharmaceutical company, has announced that its Research and Development facility at the Lupin…